Overview

Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2

Eligibility

Inclusion Criteria:

• Hospitalized with moderate, severe, or early critical COVID-19 illness diagnosed by RT- PCR
• Acute liver injury (including acute on chronic liver disease) or acute kidney injury

Exclusion Criteria:

• Critical COVID-19 illness (MAP < 60 mm Hg, on mechanical ventilator for 5 days)
• On maintenance hemodialysis or peritoneal dialysis
• Child Pugh C cirrhosis
• Hepatorenal syndrome
• Ascites and/or hepatic encephalopathy
• History of end stage renal disease or CKD with eGFR < 15 mL/min/1.73m2
• Women who are pregnant or breast feeding
• Receipt of other concomitant experimental therapies